Logo

Mylan Voluntarily Recalls Nationwide Three Lots of Nizatidine Capsules USP Due to Trace Amounts of NDMA (N-Nitrosodimethylamine)

Share this

Mylan Voluntarily Recalls Nationwide Three Lots of Nizatidine Capsules USP Due to Trace Amounts of NDMA (N-Nitrosodimethylamine)

Shots:

  • The voluntarily nationwide consumer level recall involves three lots of Nizatidine Capsules (including the 150mg and 300mg strengths) due to trace amounts of NDMA contained in API Nizatidine- USP- manufactured by Mylan Pharmaceuticals Inc
  • The recall is for the lots distributed between Jun- 2017 to Aug- 2018. Additionally- the recall is being conducted under the knowledge of the US FDA and the AEs will be reported to the FDA’s MedWatch Adverse Event Reporting program either online- by regular mail or by fax on www.fda.gov/medwatch/report.htm link
  • Nizatidine is targeted short-term treatment (up to 8 wks.) for active duodenal ulcers and active benign gastric ulcers- as maintenance therapy for duodenal ulcer patients for up to one year- and for up to 12 wks. for the treatment of endoscopically diagnosed esophagitis and associated heartburn due to gastroesophageal reflux disease (GERD)

Click here to read full press release/ article | Ref: Mylan | Image: Behance


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions